HOME NEWS EARNINGS RESULTS PICKS STRATEGY BLOG CONTACT SUBSCRIBE LOGIN SUBSCRIBE JOIN FREE
LOADING
Price Investing Group
← Back to Research Watchlist
TVTX
Travere Therapeutics Inc
Healthcare Biotechnology · California, USA · Reports in usd
Market Cap: $3.62B
Market Cap
$3.62B
Enterprise Val
$3.63B
P/E Ratio
-141.85
P/B Ratio
31.56
Trailing PEG (1Y)
1.36
As Of
Apr 23, 2026

Overview & Key Metrics

Reporting period: Dec 31, 2025 · Q4 2025
Book Value$114.8M
Gross Margin98.03%
Profit Margin98.03%
Return on Equity-40.24%
Return on Assets-4.55%
Current Ratio2.74
Debt/Equity2.86
LT Debt/Equity2.81
Revenue Per Share1.45

Income Statement

Dec 31, 2025
Revenue$129.7M
Cost of Revenue$2.6M
Gross Profit$127.1M
R&D$57.9M
SG&A$101.7M
Operating Expenses$159.6M
Operating Income-$32.4M
Interest Expense$2.3M
Tax Expense$921.0K
Net Income$2.7M
EPS (Basic)$0.03
EPS (Diluted)$0.03
EBIT$5.9M
EBITDA$24.1M
Consolidated Income$2.7M
Non-Controlling Interests$0.00

Balance Sheet

Dec 31, 2025
Cash & Equivalents$93.0M
Accounts Receivable$80.1M
Inventory$36.2M
Current Assets$437.6M
LT Investments$0.00
Property, Plant & Equipment$14.6M
Intangibles$113.9M
Non-Current Assets$167.6M
Total Assets$605.2M
Accounts Payable$24.8M
Current Debt$5.9M
Current Liabilities$159.9M
LT Debt$322.9M
Non-Current Liabilities$330.5M
Total Liabilities$490.4M
Total Debt$328.7M
Retained Earnings-$1.47B
Shareholder Equity$114.8M
Shares Outstanding89,472,327

Cash Flow Statement

Dec 31, 2025
Operating Cash Flow$60.7M
Investing Cash Flow-$104.8M
Financing Cash Flow$26.7M
CapEx-$18.9M
Free Cash Flow$41.8M
Depreciation & Amort.$18.1M
Stock-Based Comp$11.5M
Acquisitions / Disposals$0.00
Investment Activity-$85.5M
Debt Issued/Repaid$0.00
Equity Issued/Repaid$27.2M
Dividends Paid$0.00
Net Change in Cash-$17.9M
Data cached · Meta cache · Daily cache · Statements cache · TTL 24h